Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Glaxosmithkline Intellectual Property Development Limited patents


Recent patent applications related to Glaxosmithkline Intellectual Property Development Limited. Glaxosmithkline Intellectual Property Development Limited is listed as an Agent/Assignee. Note: Glaxosmithkline Intellectual Property Development Limited may have other listings under different names/spellings. We're not affiliated with Glaxosmithkline Intellectual Property Development Limited, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxosmithkline Intellectual Property Development Limited-related inventors


 new patent  Combination therapy

The present invention provides methods for increasing expression of at least one co-stimulatory and/or co-inhibitory receptor on a t cell comprising contacting said t cell with an anti-ctla4 antibody. In one aspect the co-stimulatory and/or co-inhibitory receptor is selected from the group of: pd-1, ox40, icos, cd137, tim3, and lag3. ... Glaxosmithkline Intellectual Property Development Limited

 new patent  Gdnf induction for the treatment of retinal disorders

Methods and compositions for glial cell-derived neurotrophic factor (gdnf) induction in the eye, and for treatment and/or prevention of retinal disorders are described.. . ... Glaxosmithkline Intellectual Property Development Limited

Combination treatments and uses and methods thereof

Disclosed herein are combinations of an ox40 modulator and a ctla-4 modulator, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combination, including uses in cancer.. . ... Glaxosmithkline Intellectual Property Development Limited

Combination treatments and uses and methods thereof

Disclosed herein are combinations of an ox40 modulator and a pd-1 modulator, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combination, including uses in cancer.. . ... Glaxosmithkline Intellectual Property Development Limited

Microbiological process

A process for the microbial synthesis of migalastat, specifically a process for the production of migalastat comprising culturing a microorganism under conditions such that at least one imino sugar is produced and detecting and/or isolating an imino sugar produced by said microorganism, and the microorganisms used in this process. The invention also comprises migalastat produced according to the above method and pharmaceutical compositions and uses thereof.. ... Glaxosmithkline Intellectual Property Development Limited

Novel soluble guanylate cyclase activators and their use

The invention relates to activators of soluble guanylate cyclase and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pressure in animals of the mammalian species.. ... Glaxosmithkline Intellectual Property Development Limited

Novel compounds as rearranged during transfection (ret) inhibitors

. . . . . . . . This invention relates to novel compounds which are inhibitors of the rearranged during transfection (ret) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to ret dysfunction or where modulation of ret activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (ibs) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, von hippel-lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased ret kinase activity.. . ... Glaxosmithkline Intellectual Property Development Limited

Novel compounds

. . The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of rip2 kinase, including degrading rip2 kinase, the treatment of diseases and conditions mediated by the rip2 kinase, in particular for the treatment of inflammatory diseases or conditions.. ... Glaxosmithkline Intellectual Property Development Limited

Lap e3 ligase directed proteolysis targeting chimeric molecules

. . The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of rip2 kinase, including degrading rip2 kinase, the treatment of diseases and conditions mediated by the rip2 kinase, in particular for the treatment of inflammatory diseases or conditions.. ... Glaxosmithkline Intellectual Property Development Limited

Covalent conjugates of bet inhibitors and alpha amino acid esters

The present invention relates to covalent conjugates of bet inhibitors and alpha amino acid esters, processes for their preparation, compositions containing them, and to their use in the treatment of various disorders in particular inflammatory and autoimmune diseases, such as rheumatoid arthritis; and cancers.. . ... Glaxosmithkline Intellectual Property Development Limited

Novel compounds as rearranged during transfection (ret) inhibitors

. . . . This invention relates to novel compounds which are inhibitors of the rearranged during transfection (ret) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to ret dysfunction or where modulation of ret activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (ibs) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, von hippel-lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased ret kinase activity.. . ... Glaxosmithkline Intellectual Property Development Limited

Prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

The present invention relates to the compound (2r,2′r)-bis(((((tetrahydro-2h-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid p component (sap) would be beneficial, including amyloidosis, alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.. . ... Glaxosmithkline Intellectual Property Development Limited

Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide

Disclosed are novel crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.. ... Glaxosmithkline Intellectual Property Development Limited

Topical pharmaceutical compositions

. . The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.. ... Glaxosmithkline Intellectual Property Development Limited

02/22/18 / #20180051275

Method for purifying viral vectors

The invention relates to methods of purifying viral vectors from cell culture. In particular, the invention relates to a method of purifying a supernatant containing viral vectors from a cell culture, comprising removing cells by filtering said cell culture using diatomaceous earth.. ... Glaxosmithkline Intellectual Property Development Limited

01/25/18 / #20180023122

Novel processes for the production of oligonucleotides

. . Disclosed herein are novel processes for the production of oligonucleotides that are suitable for use in the production of chemically modified oligonucleotides, such as those for use in therapy.. . ... Glaxosmithkline Intellectual Property Development Limited

01/25/18 / #20180022737

Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide

Disclosed are novel crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide, and solvates thereof and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.. ... Glaxosmithkline Intellectual Property Development Limited

01/04/18 / #20180000952

Enzyme and receptor modulation

. . Covalent conjugation of an alpha amino acid ester to a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid, leads to accumulation of the carboxylic acid hydrolysis product in the cell and enables improved or more prolonged enzyme or receptor modulation relative to the unconjugated modulator.. . ... Glaxosmithkline Intellectual Property Development Limited

12/28/17 / #20170369448

Compounds for affinity chromatography and for extending the half-life of a therapeutic agent

. . Compounds useful for affinity chromatography as presented, more particularly for use in affinity chromatography to purify serum albumin, especially human serum albumin (hsa) and fusion proteins thereof. Methods for extending the half-life of therapeutic agents are also presented, particularly therapeutic peptide agents and small molecules, such as by conjugation of compounds described herein to the therapeutic peptide or small molecule, which, upon administration, binds to hsa, thereby providing a prolonged release of the therapeutic agent.. ... Glaxosmithkline Intellectual Property Development Limited

11/30/17 / #20170340617

Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors

. . This invention relates to novel compounds which are inhibitors of the rearranged during transfection (ret) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to ret dysfunction or where modulation of ret activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (ibs) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, von hippel-lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased ret kinase activity.. . ... Glaxosmithkline Intellectual Property Development Limited

10/26/17 / #20170305888

Novel soluble guanylate cyclase activators and their use

The invention relates to activators of soluble guanylate cyclase and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pressure in animals of the mammalian species.. ... Glaxosmithkline Intellectual Property Development Limited

10/26/17 / #20170304301

Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection

The present invention relates to methods for treating neisseria gonorrhoeae infection which comprises administering to a subject in need thereof novel tricyclic nitrogen containing compounds and corresponding pharmaceutical compositions as described herein.. . ... Glaxosmithkline Intellectual Property Development Limited

10/12/17 / #20170290844

Methods of treatment

. . . . . . The present invention relates to methods of treating or preventing respiratory infections, in particular respiratory infections in patients with an underlying respiratory disorder such as chronic obstructive pulmonary disease (copd). The present invention also relates to methods of treating or preventing copd or copd exacerbations. ... Glaxosmithkline Intellectual Property Development Limited

10/05/17 / #20170283404

Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide

Disclosed are novel crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.. ... Glaxosmithkline Intellectual Property Development Limited

09/28/17 / #20170275371

Methods of treatment

Disclosed herein are combinations of an ox40 modulator and a tlr4 modulator, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combination, including uses in cancer.. . ... Glaxosmithkline Intellectual Property Development Limited

09/21/17 / #20170267665

Prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

The present invention relates to the compound (2r,2′r)-bis(((((tetrahydro-2h-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid p component (sap) would be beneficial, including amyloidosis, alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.. . ... Glaxosmithkline Intellectual Property Development Limited

09/21/17 / #20170266199

Heterocyclic amides as rip1 kinase inhibitors as medicaments

Disclosed is a method of treating a rip1 kinase-mediated disease or disorder which comprises administering a therapeutically effective amount of a compound that inhibits rip1 kinase and at least one other therapeutically active agent to a patient in need thereof.. . ... Glaxosmithkline Intellectual Property Development Limited

09/14/17 / #20170260266

Tslp binding proteins

. . The present disclosure relates to tslp binding proteins that interact with particular residues of human full length tslp, or contact particular regions of human full length tslp. The invention also includes pharmaceutical compositions and medical uses of these tslp binding proteins.. ... Glaxosmithkline Intellectual Property Development Limited

08/10/17 / #20170224685

Prmt5 inhibitors and uses thereof

. . Described herein are methods of treating cancer using one or more prmt5 inhibitors, for example using one or more compounds of formulae (1-5) or (a-f), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more prmt5 inhibitors, for example using one or more compounds of formulae (1-5) or (a-f), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.. ... Glaxosmithkline Intellectual Property Development Limited

08/10/17 / #20170224679

Use of cxcr2 antagonists for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (cipn)

The invention relates to the use of a cxcr2 antagonist for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (cipn).. . ... Glaxosmithkline Intellectual Property Development Limited

07/20/17 / #20170204108

Compounds

The present invention relates to novel compounds that inhibit lp-pla2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of lp-pla2, for example atherosclerosis, alzheimer's disease.. . ... Glaxosmithkline Intellectual Property Development Limited

07/13/17 / #20170197978

Novel compounds

The present invention relates to novel retinoid-related orphan receptor gamma (rorγ) modulators and their use in the treatment of diseases mediated by rorγ.. . ... Glaxosmithkline Intellectual Property Development Limited

07/06/17 / #20170190688

Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide

Disclosed are novel crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.. ... Glaxosmithkline Intellectual Property Development Limited

07/06/17 / #20170189424

Fluticasone furoate in the treatment of copd

The present invention relates to pharmaceutical products comprising fluticasone furoate for use in the treatment of copd patients, particularly a subgroup of copd patients that through analysis have been identified as possessing an eosinophil blood count of≧150 cells/w. The present invention is further directed to methods for treating a patient with copd which methods include identifying a patient that will respond to treatment and administering a pharmaceutical product of the present invention comprising fluticasone furoate to said patient.. ... Glaxosmithkline Intellectual Property Development Limited

06/22/17 / #20170174767

Icos binding proteins

. . The present invention relates to an icos binding protein or antigen binding portion thereof that is an agonist to human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell. ... Glaxosmithkline Intellectual Property Development Limited

06/15/17 / #20170166894

Aptamers for topical delivery

Aptamers for topical delivery and methods for topical use of aptamers are described. Aptamers that bind to interleukin (il)-23 (il-23 aptamers) and methods of using such aptamers are also described.. ... Glaxosmithkline Intellectual Property Development Limited

05/04/17 / #20170121313

Novel compounds

. . . . . . The present invention relates to novel retinoid-related orphan receptor gamma (rorγ) modulators and their use in the treatment of diseases mediated by rorγ.. . ... Glaxosmithkline Intellectual Property Development Limited

04/13/17 / #20170101399

Novel compounds

The present invention relates to novel retinoid-related orphan receptor gamma (rorγ) modulators and their use in the treatment of diseases mediated by rorγ. . ... Glaxosmithkline Intellectual Property Development Limited

01/26/17 / #20170022204

Compounds

The present invention relates to novel compounds that inhibit lrrk2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by lrrk2 kinase activity, for example parkinson's disease, alzheimer's disease and amyotrophic lateral sclerosis (als).. . ... Glaxosmithkline Intellectual Property Development Limited

01/19/17 / #20170015668

Compounds

The present invention relates to novel compounds that inhibit lrrk2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by lrrk2 kinase activity, for example parkinson's disease, alzheimer's disease and amyotrophic lateral sclerosis (als).. . ... Glaxosmithkline Intellectual Property Development Limited








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxosmithkline Intellectual Property Development Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxosmithkline Intellectual Property Development Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###